Tetronal

Tetronal is a sedative and hypnotic drug which is a barbiturate derivative. It was developed by Bayer in the late 19th century and marketed primarily in Europe and the United States. Tetronal is a Schedule III drug under the Convention on Psychotropic Substances. It is also known as tetronal or tetronal barbiturate.

History

Tetronal was first synthesized by Adolf von Baeyer in 1864. It was one of the first barbiturates to be developed and was used as a sedative and hypnotic until the mid-20th century. The drug was marketed by Bayer under the brand name "Tetronal".

Pharmacology

Tetronal is a barbiturate, a class of drugs that act as central nervous system depressants. Barbiturates work by increasing the activity of gamma-aminobutyric acid (GABA), a neurotransmitter that inhibits brain activity. This results in sedation, hypnosis, and decreased anxiety.

Medical uses

Tetronal was used as a sedative and hypnotic in the treatment of insomnia and anxiety disorders. It was also used in the treatment of epilepsy and seizure disorders.

Side effects

Common side effects of Tetronal include drowsiness, dizziness, and confusion. More serious side effects can include respiratory depression, addiction, and overdose.

Legal status

Tetronal is a Schedule III drug under the Convention on Psychotropic Substances. This means that it has a potential for abuse and dependence, but also has accepted medical uses.

See also

• Barbiturate
• Sedative
• Hypnotic
• Convention on Psychotropic Substances

Tetronal Resources
Latest articles Most recent articles Ongoing trials	Wikipedia